CDSCO Revokes Approval of Seven Ethics Committees Over Clinical Trial Rule Violations

The Central Drugs Standard Control Organisation (CDSCO) announced on Thursday that it has withdrawn the registration of seven Institutional Ethics Committees (IECs) across the country. The decision comes after the regulator found these committees repeatedly flouting the rules that govern clinical trials in India.

According to the notice, the committees failed to submit mandatory minutes, did not maintain proper documentation of trial approvals, and overlooked the mandatory conflict‑of‑interest disclosures. In short, the oversight mechanisms that protect trial participants were either missing or seriously compromised.

"Patient safety is non‑negotiable," a CDSCO spokesperson said, adding that the agency had given the committees multiple chances to rectify the gaps. "When those opportunities were ignored, we had no choice but to act," the official explained, emphasizing the regulator's commitment to upholding ethical standards.

For the affected institutions, the fallout is immediate. Any ongoing or planned clinical studies that were under the jurisdiction of the cancelled committees must now seek approval from a newly recognized IEC before they can proceed. Researchers have been urged to re‑submit their protocols, a process that could add weeks—or even months—to trial timelines.

Industry bodies, meanwhile, have welcomed the move, noting that it sends a clear message that compliance is not optional. "We have been advocating for stricter enforcement for years," said a senior official from the Indian Pharmaceutical Association. "This step by CDSCO should encourage all ethics committees to tighten their processes and be more transparent."

Patients, too, stand to benefit. Ethics committees serve as the first line of defence, reviewing study designs to ensure risks are minimized and informed consent is genuinely informed. When those committees slip, the very people the trials aim to help could be exposed to unnecessary danger.

Looking ahead, CDSCO says it will continue to audit IECs on a regular basis and will introduce a digital tracking system to monitor compliance in real time. The regulator hopes that the combination of stricter oversight and technology will prevent similar breaches in the future.

In the meantime, investigators are advised to verify the current status of their IECs before submitting any new trial applications. The CDSCO website now hosts an updated list of recognised committees, making it easier for sponsors and researchers to confirm legitimacy.